Outlook Therapeutics, Inc.
OTLKNASDAQHealthcare● Active
$0.72
$-0.05(-7.04%)
Market Cap$29703369
P/E Ratio—
52W High$3.39
52W Low$0.161
Outlook Therapeutics, Inc. (OTLK) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · OTLK · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.41M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.76M | $0.11M | $0.04M | $0.20M | $0.26M |
| Gross Profit | $0.66M | ($0.11M) | ($0.04M) | ($0.20M) | ($0.26M) |
| Gross Margin %(computed) | 46.49% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $27180640.00M | $41.76M | $26.45M | $42.33M | $38.96M |
| G&A Expenses | $39.94M | $29.94M | $26.67M | $20.74M | $12.77M |
| Total Operating Expenses | $67.72M | $71.70M | $53.13M | $62.87M | $51.73M |
| Operating Income | ($67.06M) | ($71.70M) | ($53.13M) | ($63.07M) | ($51.73M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.09M | $0.91M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.28M | $3.16M | $1.56M | $1.49M | $0.94M |
| Income Before Tax | ($63.98M) | ($75.36M) | ($58.98M) | ($66.05M) | ($53.16M) |
| Income Tax Expense | ($1.55M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($62.42M) | ($75.37M) | ($58.98M) | ($66.05M) | ($53.16M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.79 | $-4.06 | $-4.72 | $-6.23 | $-6.96 |
| Wtd Avg Shares | 34.80M | 18.55M | 12.51M | 10.60M | 7.63M |
| EBITDA | ($63.58M) | ($72.09M) | ($57.38M) | ($64.36M) | ($51.51M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Outlook Therapeutics, Inc. data
About Outlook Therapeutics, Inc. (OTLK) Income Statement
Outlook Therapeutics, Inc. (OTLK) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, OTLK reported revenue of $0.00B, gross profit of $0.00B (gross margin 46.49%), and net income of ($0.06B) — a net profit margin of -4416.22%.
Frequently asked questions
OTLK · 4 questionsOutlook Therapeutics, Inc. (OTLK) reported revenue of $0.00B for 2025, up —% year-over-year.
OTLK revenueOTLK salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09